Healthcare Business

payoff

Teva Proves Its Decade-Hold Status With Massive Funding

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) may have just proved how financially fit and capable the company is. On Friday afternoon the global generic drug giant reported that it has ...
Read Full Story »
research

Global Blood Therapeutics Updates Terms in IPO

Global Blood Therapeutics Inc. filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The expected price range is anticipated to ...
Read Full Story »
research

Amgen Earnings Point to New 52-Week High

Amgen Corp. (NASDAQ: AMGN) reported fiscal second quarter 2015 earnings Thursday afternoon after equity markets had closed. The biotech firm posted adjusted earnings per share (EPS) of $2.57 on revenues ...
Read Full Story »
153790263

Why Merrill Lynch Upgraded Aetna

Merrill Lynch upgraded Aetna Inc. (NYSE: AET) to Buy from Neutral but maintains its price objective at $132, implying an 18% upside. Since the announcement that Aetna will acquire Humana ...
Read Full Story »
biotech

What to Expect from Amgen Earnings

Amgen Inc. (NASDAQ: AMGN) is scheduled to report its earnings after the markets close on Thursday. There are consensus estimates from Thomson Reuters that call for $2.43 in earnings per ...
Read Full Story »
Prescription drugs

Are Teva Earnings Enough?

Teva Pharmaceutical Industries Limited (NYSE: TEVA) reported its second-quarter financial results Thursday before the markets opened. The company had $1.43 in earnings per share (EPS) on $5.0 billion in revenue ...
Read Full Story »
153790263

More Doctors Flee Private Practice

The old style independent doctor has continued to disappear. Practicing in a hospital has become a better financial deal, as the costs of insurance rise, and the income from visits, ...
Read Full Story »
153576724

Is This a Turning Point For Unilife?

Unilife Corp. (NASDAQ: UNIS) announced the introduction of the Imperium platform of instant patch pumps for insulin. The platform is designed for supply to a select insulin partner or partners ...
Read Full Story »
biotech

Should Gilead Really Be Rated Underperform?

Most analysts seem to be behind the growth that Gilead Sciences Inc. (NASDAQ: GILD) has seen, namely in its Hepatitis C vaccines (HCV) Harvoni and Solvaldi. For the most part ...
Read Full Story »
E000249

Who Really Won in the PDL and Ariad Royalty Deal?

The solid performance of the healthcare sector over the past year has been enhanced by mergers and acquisitions, licensing, and other forms of deals in the sector. This most recent ...
Read Full Story »
health care

GC Aesthetics Sets Expected Price Range For IPO

GC Aesthetics PLC filed an amended F-1 form with the Securities and Exchange Commission (SEC) for its initial public offering (IPO). The expected price range for the offering was given ...
Read Full Story »
Comfortable hospital bed

Humana Posts 2Q Earnings Beat

Humana Inc. (NYSE: HUM) reported its second-quarter financial results Wednesday before the markets opened. The company had $1.67 in earnings per share (EPS) on $13.73 billion in revenue compared to ...
Read Full Story »
145922793

Anthem Posts Strong Second Quarter Beat

Anthem, Inc. (NYSE: ANTM) reported its second-quarter financial results Wednesday before the markets opened. The company had $3.10 in earnings per share (EPS) on $19.76 billion in revenue compared to ...
Read Full Story »
coins

Dermira Files For Secondary Offering

Dermira, Inc. (NASDAQ: DERM) filed an S-1 form with the Securities and Exchange Commission (SEC) for a secondary offering. There were no terms given in this initial filing but the ...
Read Full Story »
gilead

Gilead Tops Estimates in 2Q

Gilead Sciences Inc. (NASDAQ: GILD) reported second-quarter financial results Tuesday after the markets closed. The biotech giant had $3.15 in earnings per share (EPS) on $8.2 billion in revenue compared ...
Read Full Story »